Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Hepatology & Tropical Medicine Research Institute
Seoul National University Hospital
Seoul National University Hospital
ANRS, Emerging Infectious Diseases
ANRS, Emerging Infectious Diseases
Sun Yat-sen University
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Innovent Biologics (Suzhou) Co. Ltd.
China Medical University Hospital
Coherus Oncology, Inc.
Centre Oscar Lambret
Federation Francophone de Cancerologie Digestive
Akeso
Sun Yat-sen University
Institute of Oncology Ljubljana
Jiangsu HengRui Medicine Co., Ltd.
Zhejiang University
University of California, San Diego
St. Jude Children's Research Hospital
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
Mayo Clinic
Merck Sharp & Dohme LLC
Radiation Therapy Oncology Group
Peking University
SOFIE
University of Washington
Anhui Provincial Hospital
Sun Yat-sen University
Bristol-Myers Squibb
Bristol-Myers Squibb
Thomas Jefferson University
First Affiliated Hospital, Sun Yat-Sen University
Guangxi Medical University
Bristol-Myers Squibb
University of Pittsburgh
Cedars-Sinai Medical Center
Hoffmann-La Roche
Sun Yat-sen University
Hospices Civils de Lyon
Mayo Clinic
Shengjing Hospital
UNICANCER
Coherus Oncology, Inc.
Milton S. Hershey Medical Center
Mayo Clinic
University of Southern California
Eisai Inc.